PST-611

About PulseSight Therapeutics

PulseSight Therapeutics is a Paris-based, clinical-stage biotechnology company pioneering a disruptive, non-viral gene therapy platform for ophthalmology. The company's core technology involves a proprietary electro-transfection delivery system that enables sustained expression of therapeutic proteins from plasmids administered into the ciliary muscle. With two lead programs in advanced Phase 1/2 development for dry and wet AMD, PulseSight is targeting a massive global market with a potential paradigm shift in treatment, moving from frequent injections to a one-time, minimally invasive gene therapy. The company is led by an experienced team and backed by leading international life science investors.

Therapeutic Areas